Peptides Curriculum • From MD to Chief Longevity Officer • Triple-Agonists • $8 Trillion Longevity Market
Issue 61: The front page of longevity medicine - curated by doctors, for doctors.
Hey Doc,
I’m writing this week’s newsletter in between friends stopping by to celebrate my son’s 11th birthday. While working on it, I also wrote him a letter because sometimes words are the most personal gift you can offer. In the same spirit, I feel privileged to share these words with you each Sunday.
Longevity medicine will soon no longer be niche become modern mecidine. From the peptide revoultion to billion-dollar labs to Mayo-backed clinics in Shanghai, the pace of change is accelerating. But no algorithm or platform can replace the one thing that matters most: Trust.
This week’s cover story is a call to action: the shift from MD to Chief Longevity Officer. Just as Kodak missed the digital revolution, doctors who resist longevity risk irrelevance. Those who lead will define the next era of medicine.
Happy birthday son! Happy sunday docs!
Dr. David Luu
Founder, Longevity Docs
www.longevitydocs.org
In this week newsletter:
🟢 Inside Longevity Docs: CLP Cohort 3 Launch • Peptides Curriculum
💬 Buzz in the Chat: GLP-1s & The Triple-Agonist Wars • ApoB, Soft Plaque, New Therapies • Cognitive & Performance Tools
📰 Cover Story: From MD to CLO: Don’t Be the Kodak of Medicine
🧠 Research Radar: Semaglutide vs. Tirzepatide in CV Risk • Medicines Repurposing & Geroscience
🌎 Longevity in the News: Xi & Putin Talk Immortality • Billionaire Longevity Bet • $8 Trillion Longevity Market
🚀 Longevity Intelligence: Parsley Longevity Labs • DNA-Powered Hair Growth System • Mayo-Backed AI-Powered Longevity Clinic
Our team is hard at work, and I’m excited to share what’s happening behind the scenes across the Longevity Docs ecosystem.
Certification Cohort 3
Invite-Only, 20 Seats
We’re opening Cohort 3 of the Certified Longevity Physician™: for practicing MDs who want evidence, outcomes, and an elite peer circle.
Invite-only. 20 seats. Request an invitation to be considered.
100% online • ~100 hours • 6–9 months.
Outcome playbooks across cardiometabolic, cognition, hormones, performance.
Cohort IRL meetups: NYC, LA, Miami, Vegas, Riyadh, Austin, SF
Join the 20 MDs graduating in 2026
Peptide Mastermind Curriculum is Live
A few years ago, 99% of doctors hadn’t heard of peptides. Today, 99% of biohackers think they’re the future. Longevity physicians can’t afford to be behind the curve. From approved peptide drugs (e.g., GLP-1s like semaglutide) to widely discussed compounds like BPC-157, peptides are everywhere—and in every headline.
What you’ll get (fast):
The science, indications, and limits (what’s proven vs. promo).
Regulation & sourcing you can defend.
Inclusion/exclusion criteria, dosing windows, AE triage, and outcomes tracking.
Why this exists: to help you learn faster than the hype, so you can practice safely, credibly, and competitively.
10 sessions • 10 faculty • physician-only
Peptides 101 for Longevity Docs — Leonard Pastrana, PharmD
Discover every physician should know from mechanisms to outcomes
Evidence-based Peptides Protocols — Elizabeth Yurth, MD
Get the peptide playbook: inclusion/exclusion, AE triage, results.
Peptides in Practice — Craig Koniver, MD
Results, revenues, and risk management for modern clinics.
The Peptides Library — Neil Paulvin, DO
Every peptide you hear about: evidence, use cases, and the hype to ignore.
Stronger or Sorrier? — Matt Cook, MD
Peptides for pain, performance, injuries, and regeneration.
Skin in the Game — Saranya Wyles, MD, PhD
Explore peptides for skin longevity: which, when, and how to prove they work.
Cardiometabolic Peptides That Work — Abid Husain, MD
What the data says on peptides and prevention of CAD, diabetes, and stroke.
Gut Feelings — Cynthia Keller, MD
Evidence-based protocols for motility and microbiome health
Keep Your License
Everything you need to know: sourcing, consent, FDA letters, 503A/503B, marketing, malpractice insurance
The Debate: Click, Ship… or Clinic?
The ethics and compliance of remote peptide programs: 503A scripts, 503B office use, and branded alternatives.
Your fastest path to peptide mastery in longevity medicine.
In-Person (NYC) - Saturday, October 4, 2025 + Private Faculty Dinner. Limited classroom seating
Virtual Access
Stream live + recording vault. Sales close Monday, 9:00 a.m. ET as we prep the 2026 Virtual Library launch.
Virtual ticket sales close Monday at 9am EST as we prepare for our Virtual Library launch in 2026.
Each week, I try to explore one idea that could advance longevity medicine and hopefully support physicians in bringing it to life.
From MD to CLO: Don’t Be the Kodak of Medicine
From Niche to Mainstream
The future of medicine won’t be led by Chief Medical Officers. It will be led by Chief Longevity Officers (CLO). Back in 2018, longevity medicine was fringe. NAD+ was for researchers, Andrew Huberman wasn’t yet a household name, and most “anti-aging” meant prevention. Fast forward to 2025: longevity is everywhere. It has leapt from labs and clinics into mainstream culture, ubiquitous, commoditized, and demanded by patients.
Every Family Needs a CLO
Every family needs a Chief Longevity Officer: someone who understands the science, psychology, and true value of care. And every physician has the chance to step into that role.
The Academic Revolution
Even the most conservative institutions are shifting. Mount Sinai, Stanford, Cleveland Clinic, and Mayo are all entering the space. Longevity medicine is moving from niche to mainstream practice. Those who resist risk becoming the Kodak of medicine: admirable on paper, irrelevant in practice.
The Future of Medical Practice
Within 10 years, every clinic will have a longevity vertical. Just as cameras became standard on every phone, longevity care will become standard in every practice. This shift is powered by education. Talks fade, but education compounds into tools, skills, and mastery.
Automation will accelerate it: labs ordered by platforms, AI designing lifestyle plans, molecules recommended by algorithms. But one element cannot be automated: trust. Families and organizations will always seek the most trustworthy physician to guide their health strategies.
The Physician Identity Shift
To lead in longevity medicine, physicians must redefine who they are:
Partner in human performance: not just treating illness, but coaching, course-correcting, and compounding long-term gains.
Data and evidence fluent: using wearables, imaging, and registries as a second stethoscope, making decisions anchored in real-world outcomes.
Team-oriented by design: integrating medicine, nutrition, mental health, and technology into one record, one playbook, and one unified promise to patients.
Ethics first: clear consent, proven indications, no false promises, and safety treated as a system, not a slogan.
Are we leaving the Kodak moment of medicine?
Longevity medicine will reshape the profession. The only question: will physicians lead the transformation?
Every week, the Longevity Docs WhatsApp group feels like a front-row seat to the future of medicine. Here’s what had doctors buzzing:
GLP-1s & The Triple-Agonist Wars
We started with Wegovy’s cardio outcomes. Then it escalated.
Retatrutide chatter: early human data with 24–32% total body weight loss and strong muscle retention (early signals).
Note on DACRA therapies: potentially even better lean mass preservation.
Clinicians swapped practicals: labs, performance add-ons (HBOT, peptides), recovery protocols.
ApoB, Soft Plaque, New Therapies
A separate thread turned into a lipidology masterclass.
Consensus: LDL/ApoB causal for ASCVD; aim ApoB <60 mg/dL in high-risk patients.
Imaging playbook: Cleerly for soft/low-density plaque; low threshold in high Lp(a) + family history.
Therapies: PCSK9i (Repatha), Leqvio (q6mo after second dose at 3 months), statin + ezetimibe; consider bempedoic acid.
Lp(a) flags: echo for Aortic Stenosis risk; discuss units (mg/dL vs nmol/L) before decisions.
Pearls: add nattokinase for thrombotic risk; don’t ignore focal plaque even with “good” lipids.
Cognitive & Performance Tools
Cognitive tools: MoCA (in-office), Cambridge Brain Sciences/Creyos, BrainCheck, WAVI.
Performance: HBOT, IV hydration, red light; labs first, then tailor.
Yes, some clinics use the $14 Amazon dynamometer; others integrate InBody + Bluetooth reports.
Join 500+ Longevity Docs Across 50 Countries
Longevity Docs is a highly vetted, invitation-only community for physicians shaping the future of longevity medicine. Apply online and connect 1:1 with our team
Each week, I highlight a few studies that caught our eyes and could shape the future of longevity medicine.
Semaglutide vs. Tirzepatide in CV Risk
Recently presented data from the real-world STEER study suggest semaglutide may outperform tirzepatide in reducing the risk of heart attack and stroke. The analysis showed stronger cardiovascular protection with semaglutide, beyond glycemic control and weight loss benefits. While both GLP-1 therapies are transformative, these findings could shape prescribing decisions for longevity-focused cardiometabolic care.
👉 Question for Longevity Docs: If semaglutide proves superior for cardiovascular outcomes, should it become the first-line GLP-1 in longevity protocols targeting heart health?
Medicines Repurposing & Geroscience
A Lancet commentary highlights the fallout from the UK’s decision to cancel its Medicines Repurposing Program, which aimed to accelerate access to new uses for existing drugs. The authors argue that repurposed therapies (like metformin, rapamycin, and others with geroscience potential) are critical for tackling age-related diseases at scale. The cancellation risks slowing progress, but also opens space for new public–private collaborations to advance drug repurposing in longevity medicine.
👉 Question for Longevity Docs: If governments pull back, how can the physician/researcher community lead the charge in repurposing existing drugs for healthy aging?
I comb through the mainstream headlines, handpick the most relevant longevity stories.
Xi & Putin Talk Immortality and Back It With Billions
In a hot-mic exchange at a Beijing parade, Xi Jinping and Vladimir Putin mused about living to 150 or even forever, citing advances in biotech and organ transplants. Behind the banter lies massive state-led investment: Russia has pledged $2.6B for anti-aging R&D, while China is funding cellular aging and rejuvenation studies. Longevity is becoming a new front in global competition for power and influence. Time
👉 Why it matters: Global powers are treating longevity as a strategic asset. Physicians will be asked to validate (or challenge) these “moonshot” programs.
The Billionaire Longevity Bet: $5B and Rising
Peter Thiel, Sam Altman, and Marc Andreessen have invested $5B+ into startups tackling cell rejuvenation, anti-aging drugs, and consumer wellness. Firms like Altos, and BioAge are raising hundreds of millions. WSJ
👉 Why it matters: Venture capital is reshaping what therapies reach clinics first. Expect faster hype cycles and pressure on doctors to separate breakthroughs from marketing.
UBS: $8 Trillion Longevity Market by 2030
A new UBS report projects longevity could become an $8T annual industry by the end of the decade, spanning drugs, consumer goods, financial services, tourism, and more. Despite regulatory hurdles, valuations are already heating up. UBS
👉 Why it matters: The market is moving faster than medical guidelines. Physicians who position themselves now will lead the practice models investors and patients demand.
Every week, I track the biggest moves in longevity: new funding rounds, partnerships, product launches, and key hires.
Parsley Launches $495 Female-Focused Longevity Labs
Parsley Health has unveiled Longevity Labs, offering women 100+ biomarker panels twice a year (far beyond the ~19 markers in routine checkups). Designed to catch early warning signs of metabolic, hormonal, and cognitive decline, the program tracks biological age, Aging Velocity™, and a Female Functional Health Score™. At $495 annually (FSA/HSA eligible), it bundles testing, insights, and supplement discounts. Parsley Health
Dermatologist-Led Brand Launches DNA-Powered Hair Growth System
Dermatologist-founded Happy Head has unveiled StrandIQ, the first DNA-driven hair growth program, using cheek-swab genetic testing to decode over 500 genes tied to scalp health and treatment response. Users receive personalized reports, lifestyle guidance, and a month of prescription treatment, aiming to eliminate trial-and-error in hair restoration. By merging genomics with dermatology, Happy Head is pushing precision wellness into the mainstream of beauty and longevity. Athletechnews
Shanghai Opens Mayo-Backed AI-powered Longevity Clinic
SinoUnited Health has launched a Mayo Clinic–guided Longevity Clinic in Shanghai, bringing international evidence-based standards to China. The program combines cardiology, neurology, endocrinology, sports medicine, nutrition, sleep, psychology, and TCM into holistic care, powered by AI-driven digital platforms. By blending global science with local innovation, the clinic aims to make longevity medicine both personalized and medical-grade, setting a new benchmark for prevention and health optimization in Asia.
Longevity Docs Peptides Mastermind
New York City | October 4, 2025
Longevity Docs Summit Cannes
Cannes, France | June 10-11, 2026
Conferences Calendar
Nubioage Clinical Longevity Summit: West Palm Beach, September 12-13, 2025
Longevity Investors Conference: Gstaad, Switzerland, September 22-25
Longevity Docs Peptides Mastermind: New York, October 4
Health Optimization Medicine Symposium: Boulder, October 17-18
Zenos Health Summit: Riyadh, October 23-25, 2025
Longevity Clinic Roundtable: Novato, December 6-8, 2025
A4M: Las Vegas, December 12-13
Hormones Mastermind Replay
For the first time, get full online access to the entire event:
✔ 10 expert-led modules
✔ Real-world protocols and case studies
✔ On-demand viewing, anytime, anywhere
No fluff, no travel: just pure, actionable hormone and longevity education.
Replay Pass: $295
Why every doctor should be a longevity doctor.
The Movement
Longevity Docs is the world’s leading collective of physicians advancing longevity medicine through education, clinical research, advisory, and exclusive experiences. With over 400 members in 50+ countries, we’re building the global infrastructure for evidence-based, personalized longevity care.
Why “Longevity Docs”?
Because we believe longevity is not a specialty — it’s a human right.
The future of medicine is proactive, not reactive. It's interdisciplinary, not isolated. It’s collaborative, data-driven, and deeply human. And it starts with us — the physicians who dare to redefine what care looks like across the decades of a patient’s life.
“Longevity Docs” isn’t just a name. It’s a statement of purpose.
Our Ecosystem
Physician Network
A trusted global collective of longevity-focused doctors exchanging protocols, referrals, and real-world clinical outcomes.Education & Certification
Earn your Certified Longevity Physician™ designation through our advanced curriculum, live masterclasses, and continuous learning tracks.Decentralized Research
Lead or participate in multicenter clinical trials and patient registries, accelerating evidence generation for healthspan optimization.Strategic Advisory
We partner with vetted longevity companies, life-science, tech, and clinics to help them grow.Global Events & Experiences
Access exclusive gatherings like the NYC Mastermind and the Cannes Longevity Summit & Awards
Who It’s For
Doctors → Join the club, get certified, grow your practice
Health Systems → Implement clinical longevity programs
Brands & Startups → Validate products, find advisors, run trials
Investors → Gain early access to insights, doctors, and deal flow
We’re not just witnessing the transformation of longevity medicine we’re building it. Together.
Subscribe to the Longevity Docs Newsletter
Stay connected with the backstage of the Longevity Docs community, a network of over 500 physicians spanning 50 countries, united in our mission to democratize longevity medicine. Explore the latest in evidence-based longevity care, gain exclusive access to physician insights, and join us in shaping the future of this transformative field.
Newsletter Disclaimer:
Just signed up for the Peptide Mastermind Virtual! 💻
Love this! Thanks David